Gilead and Galapagos announce that the listing of applications for filgotinib treatment of ADULT patients with RA will be accepted by EMA

The Europeandrug(http://Authority (EMA) has accepted applications for listing of adult patients with oral selective JAK1 inhibitor filgotinib for treating rheumatoid arthritis (RA), the u.SPharmaceutical(http://giant Gilead and partner Galapagos announced recentlyFilgotinib MAA is supported by 24-week data for phase III FINCH projectThe results showed that filgotinib had strong efficacy and long-term safety in a wide range of RA patient populations, including the previously untreated (primary) RA patient population and the group of RA patients with failed biologicsIn RA patients in different subgroups, a daily filgotinib treatment can improve clinical signs and symptoms, achieve low disease activity and treatment mitigation, and inhibit structural damageThroughout the FINCH project, the security data is consistent with the results previously reportedAbout filgotinib
filgotinib is a highly selective JAK1 inhibitor that was discovered and developed by GalapagosGilead reached a $2 billion deal with Galapagos at the end of December 2015 to jointly develop filgotinibThe partnership will help strengthen Gilead's position in the field of inflammatory diseases, which will also be a new growth point for Gilead in the future, following the hepatitis C and HIV fields 　　Currently, Gilead and Galapagos are conducting a number of studies to assess the potential of filgotinib to treat a variety of inflammatory diseases, including phase III studies that treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis a report by Pharmaceutical sin-
(http:// market research firm valuate Pharma predicts that filgotinib will be one of gidder's key product (http:// , with global sales expected to reach $1.4 billion by 2024